Arkolith/Insider Trading/SYRS/Form 4

Chee Conley

Chief Commercial OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Nov 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 1, 2023Tax withholding(F)6K$2.22$13K12K
Oct 31, 2023Option exercise(M)17K——18K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 31, 2023Option exercise(M)17K—$017K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-054167) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML